13F Portfolios

Caligan Partners LP — TANGO THERAPEUTICS INC TNGX: Quarterly 13F Position History

Caligan Partners LP has reported TANGO THERAPEUTICS INC (TNGX) on 2 13F-HR filings in Pactolio's tracked window, first appearing in Q4 2025. As of Q1 2026, the position is sized at 2,408,798 shares ($50.4M market value, 3.56% of the equity book). Quarter-over-quarter share count change: 1,321,097 (-35.4%) .

Recent initiation: Caligan Partners LP first reported TNGX on the Q4 2025 filing — fewer than three quarters of history are available.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 2,408,798 1,321,097 -35.4% $50.4M 3.56% $20.92
Q4 2025 3,729,895 $33.0M 3.02% $8.86

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Caligan Partners LP first disclose a TNGX position in 13F-HR filings?

Caligan Partners LP first reported TANGO THERAPEUTICS INC (TNGX) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.

What was Caligan Partners LP's most recent quarter-over-quarter share-count change in TNGX?

Between Q4 2025 and Q1 2026, Caligan Partners LP reduced its TNGX position by 1,321,097 shares (-35.4%), leaving 2,408,798 shares at a market value of $50.4M.

Does the implied price-per-share represent Caligan Partners LP's cost basis in TNGX?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.